(1r,4r)-N1-(pyridin-2-yl)cyclohexane-1,4-diamine | 332883-96-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (1r,4r)-N1-(pyridin-2-yl)cyclohexane-1,4-diamine
• CAS: 332883-96-2
• 化学式: C₁₁H₁₇N₃
• 分子量: 191.276
• InChiKey: QQJKATBTUNOFBF-MGCOHNPYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.13
• 重原子数：
  14.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  50.94
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  2-氟吡啶 、 trans-1,4-Diaminocyclohexane 在 potassium carbonate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 12.0h， 以20 mg的产率得到(1r,4r)-N1-(pyridin-2-yl)cyclohexane-1,4-diamine
  参考文献：
  名称：

  [EN] TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS
  [FR] TRAITEMENT DE TROUBLES NÉOPLASIQUES RÉSISTANT AUX INHIBITEURS DE CDK4/6

  摘要：

  这项发明涉及治疗涉及异常细胞增殖并对选择性CDK4/6抑制剂产生抗性的疾病的方法。

  公开号：

  WO2020206035A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'UNE PROLIFÉRATION CELLULAIRE ANORMALE
  申请人：G1 THERAPEUTICS INC

  公开号：WO2019136244A1

  公开（公告）日：2019-07-11

  This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

  这项发明涉及杂环基化合物领域，用于治疗涉及异常细胞增殖的疾病，包括但不限于肿瘤和癌症。
• FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS
  申请人：Amgen Inc.

  公开号：EP1216230A2

  公开（公告）日：2002-06-26
• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION
  申请人：G1 Therapeutics, Inc.

  公开号：US20200331925A1

  公开（公告）日：2020-10-22

  This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
• US6514964B1
  申请人：——

  公开号：US6514964B1

  公开（公告）日：2003-02-04
• [EN] FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSES DE CYCLOHEPTANE FONDU ET D'AZACYCLOHEPTANE FONDU ET LEURS PROCEDES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2001023357A2

  公开（公告）日：2001-04-05

  The invention comprises novel compounds of formula E-B-(Alk)p-Q-(Alk)q-A-G wherein G is a radical of formula (I), (II) or (III) that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated by integrin receptors, such as αvβ3, αvβ5, αvβ6 and the like. The invention encompasses novel compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of such diseases and disorders. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.